Navigation Links
Repeat steroids to premature infants linked to cerebral palsy
Date:9/20/2007

NEW YORK Repeated courses of a drug that is used to improve the survival of unborn premature babies also may increase the risk of cerebral palsy in those children, according to results from a multi-center study, funded by the National Institutes of Health and led by Ronald Wapner, M.D., professor of obstetrics and gynecology, Columbia University Medical Center and attending obstetrician and gynecologist at NewYork-Presbyterian Hospital/Columbia.

Results of the study are published in the Sept. 20, 2007 issue of the New England Journal of Medicine.

The drug a corticosteroid called betamethasone is given to women at risk of premature delivery to hasten the development of their babys lungs. One course of steroids has been shown to reduce neonatal mortality and improve lung function with little risk to the infant (citation: NIH Consensus Panel on antenatal corticosteroids, 1994).

Up until the year 2000, obstetrician-gynecologists frequently repeated the course of steroids every week, up to 10 to 11 times, in women who remained pregnant after the first course. A NIH panel that year, concerned with the lack of safety data for this practice, suggested multiple courses should be strictly reserved for patients enrolled in clinical trials.

In one of the first such trials to examine the long-term effects of the treatment on the children, women who remained pregnant a week after the initial course of corticosteroids were randomly assigned to weekly courses of corticosteroids or placebo until their babies were born.

The study, performed by members of the NIH-sponsored Maternal-Fetal Medicine Network followed a total of 556 infants at the Morgan Stanley Childrens Hospital of NewYork-Presbyterian Hospital/Columbia and 12 other sites around the country, and found that by ages two to three, the two groups of children were physically and neurologically identical, except that six out of 248 children who received multiple courses of corticosteroids had been diagnosed with cerebral palsy, compared to only 1 out of 238 children in the placebo group. The mothers of all six children with cerebral palsy in the corticosteroid group had received four or more courses of the drug.

Although the difference in number of children with cerebral palsy was not statistically significant, Dr. Wapner says that since weekly courses had no long-term benefit and potentially may harm the child, doctors should not administer multiple weekly courses of corticosteroids.


'/>"/>

Contact: Elizabeth Streich
eas2125@columbia.edu
212-305-6535
Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. New Findings for Repeated Miscarriages
2. Repeated checking causes memory distrust
3. Unexplained Repeat Cesarean Deliveries On The Rise In US
4. Repeated Heart Surgery with Older Blood Transfusion Pack More Death Risk
5. Repeated Liver Cell Proliferation, a Cause for Liver Cancer
6. Repeated Weight loss Messages Have No Effect On Couch Potatoes
7. Genes May Trigger Repeated Premature Birth In Blacks
8. Watching With Intent to Repeat Ignites Key Learning Area of Brain
9. Repeat of Heart Attack can Be Prevented by Fish Oil Supplements
10. Brain Signal Prevents Us from Repeating Mistakes
11. Repeated Brain Stimulation in Old Age can Keep Alzheimers at Bay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: